Compare AGCO Corporation (AGCO) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs Ascendis Pharma A/S — how do they compare? AGCO Corporation trades at $101.37 (market cap $7.10B), while Ascendis Pharma A/S trades at $260.65 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× AGCO Corporation's market cap, and AGCO Corporation pays a 1.18% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AGCO | ASND | |
|---|---|---|
Market Cap | $7.10B | $16.67B |
Sector | Industrials | Health |
52-Week High | $140.49 | $277.18 |
52-Week Low | $100.14 | $189.74 |
Enterprise Value | $9.37B | $17.04B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $101.55, up 0.67% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed estimates, leading to an 11% share drop and multiple legal investigations. The company maintains a solid balance sheet with $612M cash and a 5.15% net income margin, but faces headwinds from lowered 2026 guidance and weak agricultural demand.
The outlook is cautious; while valuation ratios like P/E of 14.03 appear attractive and analysts set a $124.63 consensus target, risks from earnings volatility, legal scrutiny, and industry softness outweigh near-term opportunities. Investors should weigh the dividend yield against potential further downside from ongoing investigations and macroeconomic pressures.
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
